A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A-Reference-Cited by-同舟云学术

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Published:2023-03 Issue:3 Volume:21 Page:534-545
ISSN:1538-7836
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:Journal of Thrombosis and Haemostasis

Author:

Shima Midori,Amano Kagehiro,Ogawa Yoshiyuki,Yoneyama Koichiro,Ozaki Ryoto,Kobayashi Ryota,Sakaida Emiko,Saito Makoto,Okamura Takashi,Ito Toshihiro,Hattori Norimichi,Higasa Satoshi,Suzuki Nobuaki,Seki Yoshinobu,Nogami Keiji

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation;Collins;Blood,2007

2. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2);Knoebl;J Thromb Haemost,2012

3. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study;Tiede;Blood,2015

4. International recommendations on the diagnosis and treatment of acquired hemophilia A;Tiede;Haematologica,2020

5. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study;Zanon;Thromb Res,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11

2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

3. Hémophilie acquise : quoi de neuf en 2024 ?;La Revue de Médecine Interne;2024-09

4. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy;Thrombosis and Haemostasis;2024-08-12

5. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A;Journal of Thrombosis and Haemostasis;2024-07